Cancer Stem Cell News Volume 3.07 | Feb 26 2014

Analysis of the Tumor-Initiating and Metastatic Capacity of PDX1-Positive Cells from the Adult Pancreas
The authors sought to determine which subsets of pancreatic and duodenal homeobox 1 (PDX1)+ cells may be responsible for tumor growth. Using the Lox-Stop-Lox-KrasG12D genetic mouse model of pancreatic carcinogenesis, they isolated a population of KrasG12D-expressing PDX1+ cells with an inherent capacity to metastasize. [Proc Natl Acad Sci USA] Abstract

Effect of Niclosamide on Basal-Like Breast Cancers
Aldehyde dehydrogenase (ALDH) is a known marker of cancer stem cells. By testing basal-like breast cancer cells for ALDH expression by flow cytometry, investigators were able to isolate a non-adherent population of cells that have high ALDH expression. [Mol Cancer Ther] Abstract

Patients with CD133-Negative Colorectal Liver Metastasis Have a Poor Prognosis after Hepatectomy
Resected specimens were obtained surgically from 1998 to 2008 at a university hospital. Researchers investigated whether the status of two primary lesion cancer stem biomarkers, CD44 and CD133, were maintained in liver metastasis (L-Mets) and whether these markers were L-Mets prognostic factors. [Ann Surg Oncol] Abstract

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells
Researchers investigated the function and the underlying mechanism of 36 kDa full-length estrogen receptor-α (ER-α36)-mediated rapid estrogen signaling in growth regulation of the ER-positive breast cancer stem/progenitor cells. [PLoS One] Full Article

USP22 Is a Positive Regulator of NFATc2 on Promoting IL2 Expression
Investigators showed that ubiquitin-specific protease 22 (USP22), known as a cancer stem cell marker, specifically interacted with and deubiquitinated nuclear factor of activated T cells, cytoplasmic 2 (NFATc2). [FEBS Lett] Abstract

The NFκB Inhibitor, SN50, Induces Differentiation of Glioma Stem Cells and Suppresses Their Oncogenic Phenotype
Scientists show that SN50, a cell-permeable peptide inhibitor of NFκB, induced robust differentiation of human glioma stem-like cells, causing loss of their oncogenic potential. [Cancer Biol Ther] Full Article

Knockdown of 14-3-3ζ Enhances Radiosensitivity and Radio-Induced Apoptosis in CD133⁺ Liver Cancer Stem Cells
Researchers investigated whether silencing 14-3-3ζ affects the radioresistance of cancer stem-like cells (CSCs) in hepatocellular carcinoma. Knockdown of 14-3-3ζ decreased cell viability and the number of spheres by reducing radioresistance in CSCs after γ-irradiation. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

OncoMed Pharmaceuticals Commences Third Phase Ib Clinical Trial for OMP-54F28 (Fzd8-Fc) with Carboplatin and Paclitaxel in Ovarian Cancer
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells announced the initiation of patient treatment for its third multi-center Phase Ib clinical trial of OMP-54F28 with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. [OncoMed Pharmaceuticals, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center & Research Institute)

Postdoctoral Researcher – Molecular Biology and Cancer Research (Washington State University)

Postdoctoral Position – Molecular Mechanisms of Cell Division (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Stem Cell Signaling and Epigenetics (Fondazione Istituto Nazionale Genetica Molecolare)

Research Assistant – Stem Cell & Leukemia Epigenetic (King’s College London)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Postdoctoral Position – Epigenetics and Cancer Biology (MPI Bad Nauheim)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.